The changes and clinical significance of serum visfatin and adiponectin levels in patients with coronary heart disease

Abstract

Abstract: Objective　To investigate the relationship of serum visfatin， adiponectin and coronary heart disease with C reactive protein (CRP) and its possible mechanism. Methods　A total of 270 patients with coronary heart disease confirmed by coronary angiography were enrolled. According to clinical manifestations, they were classified into 3 groups：stable angina pectoris （SAP） group (125 cases), unstable angina pectoris （UAP） group (109 cases) and acute myocardial infarction （AMI） group (36 cases). Another 20 healthy subjects were as control group. The serum visfatin and adiponectin levels were determined by enzyme-linked immunosorbent assay (ELISA). The levels of CRP, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting glucose (FPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN) and creatinine (Cr) were also determined. The multiple correlation analysis method was used to analyze the correlation of visfatin and adiponectin with other indices. Results　In the coronary heart disease group, CRP and serum visfatin levels were significantly higher than those in control group（P<0.01）. The serum adiponectin level was lower than that of control group （P<0.01）. In AMI group， UAP group and SAP group, CRP， serum visfatin and adiponectin were statisically significant （P< 0.05）. The multiple correlation analysis showed that serum visfatin was positively correlated with CRP， TG and LDL-C （r=0.929，0.756 and 0.793, P<0.001）. The serum visfatin was negatively correlated with adiponectin and HDL-C （r=-0.351 and -0.699,P<0.001）. The serum adiponectin was negatively correlated with CRP, TG and LPL-C (r=-0.873，-0.639 and -0.799, P<0.001), and was positively correlated with HDL-C (r=0.681,P<0.001). Conclusions　Serum visfatin and adiponectin may be risk factors for coronary heart disease， and they may interact with CRP，and be involved in the occurrence and development of coronary heart disease.

Key words: C reactive protein, Adiponectin, Visfatin, Coronary heart disease

JIAO Lu-Yang;WANG Yu;YUAN Yu. The changes and clinical significance of serum visfatin and adiponectin levels in patients with coronary heart disease[J]. , 2012, 27(5): 349-351.

References

［1］Curat CA， Wegner V， Sengenes C， et al. Macrophages in human visceral adipose tissue： increased accumulation in obesity and a source of resistin and visfatin［J］. Diabetologia， 2006， 49（4）：744-747.
［2］Koenig W，Lowel H，Baumert J，et al. C-reactive protein modulates risk prediction based on the Framingham score： implications for future risk assessment： results from a large cohort study in southern Germany[J]. Circulation，2004，109（11）：1349-1353.
［3］Ridker PM.High-sensitivity C-reactive protein： potential adjunct for global risk assessment in the primary prevention of cardiovascular disease［J］. Circulation，2001，103（13）：1813-1818.
［4］Adya R， Tan BK， Punn A， et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways：novel insights into visfatin-induced angiogenesis［J］. Cardiovasc Res，2008，78（2）：356-365.
［5］Jones CB， Sane DC， Herrington DM. Matrix metallo-proteinases： a review of their structure and role in acute coronary syndrome［J］. Cardiovasc Res，2003，59（4）：812-823.
［6］Ouchi N，Kihara S，Arita Y，et al.Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages［J］.Circulation，2001，103（8）：1057-1063.
［7］Matsuda M， Shimomura I， Sata M， et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis［J］. J Biol Chem，2002，277（40）：37487-37491.
［8］胡　晖，张怀勤，陈达开，等. 外周血内脂素水平与冠心病的相关性［J］．中国动脉硬化杂志， 2009，17（8）：692-694．
［9］Ouchi N，Kihara A，Funahashi T，et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue［J］. Circulation，2003，107（5）：671-674.
［10］Engeli S，Feldpausch M，Gorzelniak K，et al. Association between adiponectin and mediators of inflammation in obese women［J］. Diabetes，2003，52（4）：942-947.

[1]	MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664.
[2]	WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589.
[3]	LIU Jinyan, ZHAO Juntao, XIANG Mingjie. Mechanism and application of serum amyloid A in clinical diseases [J]. Laboratory Medicine, 2021, 36(7): 756-760.
[4]	WANG Linlin, FAN Jun, YE Chenyu, YING Chunmei. Correlation between blood lipid and carotid atherosclerotic plaque in elderly patients with coronary heart disease [J]. Laboratory Medicine, 2021, 36(6): 618-622.
[5]	ZHANG Xilin, SHEN Yifeng, ZHU Jing, ZHANG Chunyan, SHAO Wenqi, WANG Beili, GUO Wei. Roles of AST,m-AST and m-AST/AST in preoperative and postoperative evaluation of patients with CHD and AMI [J]. Laboratory Medicine, 2021, 36(5): 471-476.
[6]	GUO Weidong, FU Yun, GAO Shanglan. Relationship between plasma APN,sRAGE and the prognosis of patients with ARDS [J]. Laboratory Medicine, 2021, 36(11): 1097-1100.
[7]	ZHOU Zhongwei, JU Huixiang, JIN Hao, CHEN Hongmei, SUN Mingzhong. Relationship between alpha 2-Heremans-Schmid glycoprotein to adiponectin ratio and type 2 diabetes mellitus complicated with metabolic syndrome [J]. Laboratory Medicine, 2020, 35(5): 414-419.
[8]	WANG Beili, LI Huijun, WU Yan’an, DAI Wanru, LI Yihao, GUO Wei, PAN Baishen. Correlation between serum biochemical parameters and the degree of coronary artery stenosis in patients with coronary heart disease [J]. Laboratory Medicine, 2020, 35(1): 6-10.
[9]	SHU Ming, JIN Lu, CHEN Qiuying. Role of serum hepcidin in the diagnosis of myocardial damage among coronary heart disease patients [J]. Laboratory Medicine, 2019, 34(9): 783-786.
[10]	TONG Minghong, DING Hui, JIANG Yinting, SUN Hanxiao, XUAN Binbin, SHENG Huiming. Role of the determination of statin metabolism-related gene in the treatment of cardiovascular and cerebrovascular diseases [J]. Laboratory Medicine, 2019, 34(6): 491-497.
[11]	XU Liming, SHEN Jun. Role of serum adiponectin determination combined with leptin in the diagnosis of lupus nephritis [J]. Laboratory Medicine, 2019, 34(5): 401-404.
[12]	DING Ning, CHEN Changqiang, FAN Qishi. Correlations of RDW and TB with coronary heart disease and the extent of coronary atherosclerosis [J]. Laboratory Medicine, 2019, 34(10): 889-893.
[13]	YANG Xuesong, SUN Fenyong, LI Zebing, WANG Jian. Roles of nitric oxide,endothelin-1 and homocysteine for the auxiliary diagnosis of coronary heart disease [J]. Laboratory Medicine, 2018, 33(4): 316-320.
[14]	ZHANG Shaohong, SHEN Xuebin. CYP2C19 gene polymorphism in the drug therapy of coronary heart disease [J]. Laboratory Medicine, 2018, 33(11): 979-982.
[15]	YANG Yan, ZHANG Fujun, SHEN Songkun, WANG Houzhao. NT-proBNP,cTnI,Hcy,DD and hs-CRP for the diagnosis of coronary heart disease by ROC curves [J]. Laboratory Medicine, 2018, 33(1): 15-19.